<DOC>
	<DOCNO>NCT02564861</DOCNO>
	<brief_summary>This randomise , double-blind , placebo-controlled multiple dose study design explore safety , tolerability PK DS-1971a follow oral administration 14 day healthy male female subject .</brief_summary>
	<brief_title>DS-1971a Multiple Dose Study</brief_title>
	<detailed_description />
	<criteria>Healthy male female subject age 18 year 65 year . A body mass index ( BMI ) range 18 kg/m2 30 kg/m2 , inclusive , weigh 50 kg 100 kg , inclusive screening . BMI calculate weight [ kg ] / ( height [ ] ) 2 . Female subject must nonchildbearing potential follow : Must postmenopausal ( last menstrual period least 12 month Screening , follicle stimulate hormone [ FSH ] test Screening confirms postmenopausal status ) ; Must surgically sterile undergone hysterectomy , bilateral oophorectomy , bilateral salpingectomy and/or bilateral tubal ligation . Willing comply study restriction , include use contraception , concomitant medication , dietary lifestyle restriction . Sufficient intelligence understand nature study hazard participate . Ability communicate satisfactorily Investigator participate , comply requirement , entire study . Have give write consent participate study read ICF , opportunity discus study Investigator delegate . Have give write consent his/her data enter The Over volunteering Prevention System . Clinically relevant abnormal history , physical finding , ECG finding , laboratory value could interfere objective study compromise safety subject . Presence history acute chronic illness , include ( limited ) liver kidney disease , hypertension , seizure , know impairment endocrine , specific bodyorgan dysfunction . History serious reaction medicine . Presence history malignant disease . Acute chronic infectious disease , include human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) C virus ( HCV ) infection . Surgery ( eg , stomach bypass ) medical condition might affect body handle absorb medicine . Significant illness within 4 week first dose study medication . Participation another clinical study new chemical entity prescription medicine within previous 3 month , unwilling abstain participate clinical trial study 3 month receipt study medication . Blood pressure ( BP ) heart rate semisupine position Screening examination outside range 90 mmHg 140 mmHg systolic , 40 mmHg 90 mmHg diastolic ; heart rate &lt; 40 beats/min &gt; 100 beats/min . Subjects Stage 1 hypertension ( systolic 140 mmHg 160 mmHg ; diastolic 90 mmHg 100 mmHg ) may enrol provide evidence endorgan damage , diabetes 10 year cardiovascular risk &gt; 20 % . Abnormal ECG waveform morphology Screening would preclude accurate measurement uncorrected QT interval ( QT ) duration . QT interval heart rate correct use QTcF interval duration &gt; 430 m men &gt; 450 ms woman , obtain average measurement duplicate Screening ECGs brief recording period . Estimated glomerular filtration rate ( eGFR ) &lt; 80 mL/min/1.73m2 ( base Modification Diet Renal Disease [ MDRD ] equation ) absolute creatinine value outside normal range . Use prescription counter ( OTC ) medication , herbal remedy ( St John 's wort ) , know strong inhibitor strong inducer cytochrome ( CYP ) enzyme ( also know CYP P450 enzymes ) 30 day first dose study medication ; use prescription OTC medicine ( exception acetaminophen ( paracetamol ) ) , include dietary supplement herbal remedy , 7 day dose study medication . Pregnant breastfeed woman . Consumption certain food beverage first dose throughout study period . Loss 400 mL blood donation blood , plasma , platelet , blood component 3 month first dose study medication , unwilling abstain study 3 month receipt study medication . Abuse drug alcohol 2 year first dose study medication , intake 21 unit alcohol weekly male subject 14 unit alcohol weekly female subject . Use tobacco product nicotinecontaining product 3 month first dose study medication study . Evidence drug alcohol abuse screen admission . Likely possibility volunteer cooperate requirement protocol . Objection General Practitioner ( GP ) volunteer enter study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>pharmacokinetics</keyword>
</DOC>